QoL · postmenopausal women with osteoporosis and CKD stages 5 and 5D
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical fracture · postmenopausal women with osteoporosis and CKD stages 3‐4
Any anti‐osteoporotic drugs showed no clear difference in clinical fracture compared with placebo (moderate certainty).
1 finding from 1 review
Mean change in BMD of the femoral neck · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
Mean change in BMD of the lumbar spine · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
Total hip BMD · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
Mean change in BMD of the distal radius · postmenopausal women with osteoporosis and CKD stages 3‐4
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · postmenopausal women with osteoporosis and CKD stages 3‐4
Any anti‐osteoporotic drugs showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Death · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
QoL · postmenopausal women with osteoporosis and CKD stages 3‐4
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (all causes) · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower all‐cause death median compared with placebo (high certainty).
All symptomatic CMV disease · solid organ transplant recipients
Antiviral prophylaxis leads to lower CMV disease: all symptomatic CMV disease compared with placebo or no treatment (high certainty).
1 finding from 1 review
Death associated with CMV disease · solid organ transplant recipients
Antiviral prophylaxis probably leads to lower death due to CMV disease compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
All‐cause death · solid organ transplant recipients
Antiviral prophylaxis leads to lower all‐cause death compared with placebo or no treatment (high certainty).
1 finding from 1 review
CMV infection · solid organ transplant recipients
Antiviral prophylaxis leads to lower CMV infection compared with placebo or no treatment (high certainty).
1 finding from 1 review
Graft loss · solid organ transplant recipients
Antiviral prophylaxis showed no clear difference in graft loss compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Acute rejection · solid organ transplant recipients
Antiviral prophylaxis showed no clear difference in acute rejection compared with placebo or no treatment (high certainty).
1 finding from 1 review
Leucopenia · solid organ transplant recipients
Antiviral prophylaxis showed no clear difference in leucopenia compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Kidney dysfunction · solid organ transplant recipients
Antiviral prophylaxis showed no clear difference in kidney dysfunction compared with placebo or no treatment (low certainty).
1 finding from 1 review
Death (any cause) · people IgA nephropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Kidney failure or doubling of SCr · people IgA nephropathy
Renin‐angiotensin system inhibition showed no clear difference in kidney failure or doubling of SCr compared with placebo or no treatment (low certainty).
1 finding from 1 review